Trial Profile
Effect of pembrolizumab and simultaneous radiotherapy in patients with advanced melanoma in the French early access program
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 08 Oct 2020
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Expanded access; Therapeutic Use
- Acronyms HORIZON
- 21 Sep 2020 Results (n=705; as of 18 Nov 2019) presented at the 45th European Society for Medical Oncology Congress.
- 22 Jun 2018 New trial record
- 05 Jun 2018 Results assessing the outcomes of pembrolizumab treatment in elderly melanoma patients (n=160) presented at the 54th Annual Meeting of the American Society of Clinical Oncology